Didier Bagnol, Ph. D.

Didier Bagnol, Ph.D. has extensive experience in the field of pharmacology and preclinical development. Didier began their career in 1994 as a Post Doctoral Research Fellow at the University of Michigan Medical School, where they studied hypothalamic pathways and neurons involved in the regulation of food intake and the role of the melanocortin receptor endogenous antagonist agouti related protein (Agrp). In 1998, they moved to the Université Paul Cézanne as an Associate Professor, where they established a new program to investigate the role of dorsal vagal complex visceral signals in the modulation of hypothalamic pathways involved in the regulation of energy homeostasis and obesity. Didier then joined Arena Pharmaceuticals, Inc. in 2001 as a Research Director, where they led multidisciplinary teams of scientists that successfully identified small-molecule lead compounds for orphan GPCRs, developed in vivo pharmacology rodent models and supported drug discovery programs, clinical candidate evaluation as well as partnerships and collaborations with big pharmaceutical companies. In 2008, they worked as a Consultant Neuroscience at Tocagen, where they established a translational mouse model for the treatment of brain cancers. Didier then worked as a Consultant Pharmacology & Preclinical Development at Bagnol Consulting from 2016 to 2018, where they served as an independent consultant and advisor for various Biotech and mid-size biopharmaceutical companies. In 2018, they joined Conatus Pharmaceuticals Inc. as a Director Pharmacology, and then moved to Trefoil Therapeutics as a Director Of Research Development in 2020. Most recently, they joined Epirium as a Senior Director Preclinical Pharmacology and Translational Sciences in 2021, where they developed in vitro and vivo models to identify and evaluate the efficacy of 15-PGDH small molecule inhibitors, selected and managed CROs for contracted studies, managed in vitro screening assays, PK and Biodistribution studies, and designed in vivo studies for the evaluation of compounds efficacy in rodent models of Spinal Muscle Atrophy, muscle-injury, and sarcopenia as well as pulmonary and myocardial fibrosis. Didier is currently a Director in vivo Pharmacology at Pipeline Therapeutics.

Didier Bagnol, Ph.D. has an extensive education history. Didier obtained their Bachelor's degree in Physiology-Neurophysiology from Université Paul Cézanne in 1984-1989. Didier then earned their Master's degree-eq DEA in Neurobiology and Neurosciences from Université Paul Cézanne in 1989-1990. Didier followed this up with a Dr. Sc. (Ph.D.) in Neurosciences & Physiology from Aix-Marseille University in 1990-1994. Finally, they completed a Post doctoral Fellow in Neurobiology and Neurosciences at the University of Michigan Medical School in 1994-1998.